Litcius/Paper detail

Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model

Roghayeh Navabi, Babak Negahdari, Ensiyeh Hajizadeh‐Saffar, Mostafa Hajinasrollah, Yaser Jenab, Shahram Rabbani, Mohamad Pakzad, Seyedeh‐Nafiseh Hassani, Maryam Hezavehei, Mohammad Jafari Atrabi, Yaser Tahamtani, Hossein Baharvand

2021Life Sciences30 citationsDOI

Topics & Concepts

LiraglutideMedicineStreptozotocinAgonistStem-cell therapyDiabetes mellitusMesenchymal stem cellInternal medicineEndocrinologyIsletReceptorTransplantationType 2 diabetesPathologyPancreatic function and diabetesMesenchymal stem cell researchDiabetes and associated disorders
Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model | Litcius